Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00220116
Status:
COMPLETED
Last Update Posted:
2010-01-06
First Post:
2005-09-19
Brief Title:
Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer
Sponsor:
Royal Marsden NHS Foundation Trust
Organization:
Royal Marsden NHS Foundation Trust
Study Overview
Official Title:
A Phase II Trial Assessing the Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the efficacy and safety of the combination of capecitabine and oxaliplatin in the 1st 2nd or subsequent line treatment of metastatic colorectal cancer and also in the neo-adjuvant and adjuvant setting of resectable metastases
Primary Endpoint Objective response rates
Secondary Endpoints Treatment related toxicity Progression free survival If not resected Disease free Survival From metastastectomy if resected Overall Survival 60 Day all cause mortality Number undergoing liver resectionscurative resection Ro rate
Primary Endpoint Objective response rates
Secondary Endpoints Treatment related toxicity Progression free survival If not resected Disease free Survival From metastastectomy if resected Overall Survival 60 Day all cause mortality Number undergoing liver resectionscurative resection Ro rate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None